90 results on '"Wachter DL"'
Search Results
2. Reduzierte Detyrosinierung von alpha-Tubulin in fetoplazentaren Gefäßen der Präeklampsie
- Author
-
Huebner, H, additional, Knörr, B, additional, Betzler, A, additional, Hartner, A, additional, Kehl, S, additional, Baier, F, additional, Wachter, DL, additional, Strick, R, additional, Beckmann, MW, additional, Fahlbusch, FB, additional, and Rübner, M, additional
- Published
- 2018
- Full Text
- View/download PDF
3. Zell-Zell-Fusion von Monozyten zu Osteoclast-like Zellen und deren Inhibiton durch Chemo- und Immuntherapeutika
- Author
-
Rübner, M, additional, Detsch, R, additional, Boccaccini, AR, additional, Strasser, E, additional, Steininger, PA, additional, Steigleder, R, additional, Wachter, DL, additional, Hübner, H, additional, Strissel, P, additional, Fasching, PA, additional, Beckmann, MW, additional, and Strick, R, additional
- Published
- 2018
- Full Text
- View/download PDF
4. Assessment of clinical potential of X-ray dark-field imaging for breast cancer
- Author
-
Emons, J, additional, Wunderle, M, additional, Emons, PA, additional, Heindl, F, additional, Rieger, J, additional, Horn, F, additional, Pelzer, G, additional, Ritter, A, additional, Weber, T, additional, Radicke, M, additional, Polifka, I, additional, Wachter, DL, additional, Wenkel, E, additional, Michel, T, additional, Uder, M, additional, Hartmann, A, additional, Anton, G, additional, Beckmann, MW, additional, Schulz-Wendtland, R, additional, and Jud, SM, additional
- Published
- 2018
- Full Text
- View/download PDF
5. Prädiktion der kompletten pathologischen Remission nach neoadjuvanter Chemotherapie durch Ki-67, den Östrogen- und Progesteronrezeptor
- Author
-
Gaß, P, primary, Bani, M, additional, Bayer, CM, additional, Beckmann, MW, additional, Erber, R, additional, Hartmann, A, additional, Häberle, L, additional, Hein, A, additional, Heusinger, K, additional, Lux, MP, additional, Rauh, C, additional, Schulz-Wendtland, R, additional, Schrauder, MG, additional, Wachter, DL, additional, and Fasching, PA, additional
- Published
- 2016
- Full Text
- View/download PDF
6. Eine neoadjuvante Carboplatin-haltige Therapie zeigt bei Patientinnen mit Brustkrebs nach Grading eine unterschiedliche pathologische Komplettremissionsrate (pCR)
- Author
-
Gaß, P, primary, Bani, M, additional, Beckmann, MW, additional, Fiessler, C, additional, Hartmann, A, additional, Hein, A, additional, Heimrich, J, additional, Lux, MP, additional, Schrauder, MG, additional, Strahl, O, additional, Rauh, C, additional, Schulz-Wendtland, R, additional, Wachter, DL, additional, and Fasching, PA, additional
- Published
- 2016
- Full Text
- View/download PDF
7. Immunhistochemische Charakterisierung molekularer Subtypen des mammären Morbus Paget
- Author
-
Wachter, PW, primary, Strehl, JD, additional, Beckmann, MW, additional, Fasching, PA, additional, Hartmann, A, additional, and Wachter, DL, additional
- Published
- 2016
- Full Text
- View/download PDF
8. Expression und Dysregulation Vitamin-A abhängiger Gene (RARRES1, 2 und 3) in der humanen Plazenta
- Author
-
Huebner, H, primary, Engelbrecht, J, additional, Fellermeyer, M, additional, Fahlbusch, F, additional, Wachter, DL, additional, Strick, R, additional, Beckmann, MW, additional, and Ruebner, M, additional
- Published
- 2016
- Full Text
- View/download PDF
9. Expression der MARCH-Gene im Mammakarzinom
- Author
-
Wuerfel, FM, primary, Strick, R, additional, Strissel, PL, additional, Wachter, DL, additional, Fasching, PA, additional, Beckmann, MW, additional, and Rübner, M, additional
- Published
- 2016
- Full Text
- View/download PDF
10. Identifizierung neuer Targets für CAR-modifizierte T-Zellen im Mammakarzinom
- Author
-
Würfel, FM, primary, Hein, A, additional, Strick, R, additional, Strissel, PL, additional, Wachter, DL, additional, Fasching, PA, additional, Beckmann, MW, additional, and Rübner, M, additional
- Published
- 2015
- Full Text
- View/download PDF
11. Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study
- Author
-
Koebel, M, Madore, J, Ramus, SJ, Clarke, BA, Pharoah, PDP, Deen, S, Bowtell, DD, Odunsi, K, Menon, U, Morrison, C, Lele, S, Bshara, W, Sucheston, L, Beckmann, MW, Hein, A, Thiel, FC, Hartmann, A, Wachter, DL, Anglesio, MS, Hogdall, E, Jensen, A, Hogdall, C, Kalli, KR, Fridley, BL, Keeney, GL, Fogarty, ZC, Vierkant, RA, Liu, S, Cho, S, Nelson, G, Ghatage, P, Gentry-Maharaj, A, Gayther, SA, Benjamin, E, Widschwendter, M, Intermaggio, MP, Rosen, B, Bernardini, MQ, Mackay, H, Oza, A, Shaw, P, Jimenez-Linan, M, Driver, KE, Alsop, J, Mack, M, Koziak, JM, Steed, H, Ewanowich, C, DeFazio, A, Chenevix-Trench, G, Fereday, S, Gao, B, Johnatty, SE, George, J, Galletta, L, Goode, EL, Kjaer, SK, Huntsman, DG, Fasching, PA, Moysich, KB, Brenton, JD, Kelemen, LE, Koebel, M, Madore, J, Ramus, SJ, Clarke, BA, Pharoah, PDP, Deen, S, Bowtell, DD, Odunsi, K, Menon, U, Morrison, C, Lele, S, Bshara, W, Sucheston, L, Beckmann, MW, Hein, A, Thiel, FC, Hartmann, A, Wachter, DL, Anglesio, MS, Hogdall, E, Jensen, A, Hogdall, C, Kalli, KR, Fridley, BL, Keeney, GL, Fogarty, ZC, Vierkant, RA, Liu, S, Cho, S, Nelson, G, Ghatage, P, Gentry-Maharaj, A, Gayther, SA, Benjamin, E, Widschwendter, M, Intermaggio, MP, Rosen, B, Bernardini, MQ, Mackay, H, Oza, A, Shaw, P, Jimenez-Linan, M, Driver, KE, Alsop, J, Mack, M, Koziak, JM, Steed, H, Ewanowich, C, DeFazio, A, Chenevix-Trench, G, Fereday, S, Gao, B, Johnatty, SE, George, J, Galletta, L, Goode, EL, Kjaer, SK, Huntsman, DG, Fasching, PA, Moysich, KB, Brenton, JD, and Kelemen, LE
- Abstract
BACKGROUND: Folate receptor 1 (FOLR1) is expressed in the majority of ovarian carcinomas (OvCa), making it an attractive target for therapy. However, clinical trials testing anti-FOLR1 therapies in OvCa show mixed results and require better understanding of the prognostic relevance of FOLR1 expression. We conducted a large study evaluating FOLR1 expression with survival in different histological types of OvCa. METHODS: Tissue microarrays composed of tumour samples from 2801 patients in the Ovarian Tumour Tissue Analysis (OTTA) consortium were assessed for FOLR1 expression by centralised immunohistochemistry. We estimated associations for overall (OS) and progression-free (PFS) survival using adjusted Cox regression models. High-grade serous ovarian carcinomas (HGSC) from The Cancer Genome Atlas (TCGA) were evaluated independently for association between FOLR1 mRNA upregulation and survival. RESULTS: FOLR1 expression ranged from 76% in HGSC to 11% in mucinous carcinomas in OTTA. For HGSC, the association between FOLR1 expression and OS changed significantly during the years following diagnosis in OTTA (Pinteraction=0.01, N=1422) and TCGA (Pinteraction=0.01, N=485). In OTTA, particularly for FIGO stage I/II tumours, patients with FOLR1-positive HGSC showed increased OS during the first 2 years only (hazard ratio=0.44, 95% confidence interval=0.20-0.96) and patients with FOLR1-positive clear cell carcinomas (CCC) showed decreased PFS independent of follow-up time (HR=1.89, 95% CI=1.10-3.25, N=259). In TCGA, FOLR1 mRNA upregulation in HGSC was also associated with increased OS during the first 2 years following diagnosis irrespective of tumour stage (HR: 0.48, 95% CI: 0.25-0.94). CONCLUSIONS: FOLR1-positive HGSC tumours were associated with an increased OS in the first 2 years following diagnosis. Patients with FOLR1-negative, poor prognosis HGSC would be unlikely to benefit from anti-FOLR1 therapies. In contrast, a decreased PFS interval was observed for FOLR1-positive
- Published
- 2014
12. Einfluss des Pneumoperitoneums auf den Verlauf der schweren akuten Pankreatitis mit infizierter Nekrose
- Author
-
Wachter, DL, Strobel, O, Werner, J, Müller, CA, Uhl, W, Khalik, M, Büchler, MW, and Gutt, CN
- Subjects
ddc: 610 - Published
- 2004
13. Prädiktion der kompletten pathologischen Remission nach neoadjuvanter Chemotherapie durch den Östrogenrezeptor
- Author
-
Gaß, P, primary, Häberle, L, additional, Hein, A, additional, Heusinger, K, additional, Bayer, CM, additional, Rauh, C, additional, Schulz-Wendtland, R, additional, Bani, M, additional, Schrauder, MG, additional, Lux, MP, additional, Wachter, DL, additional, Hartmann, A, additional, Fasching, PA, additional, and Beckmann, MW, additional
- Published
- 2014
- Full Text
- View/download PDF
14. Diagnostische Vorhersagekraft von Ultraschall, ARFI Elastrografie und minilaparokopisch unterstützter Biopsie zur Diagnose oder Ausschluss der kompensierten Leberzirrhose
- Author
-
Pfeifer, L, primary, Zopf, S, additional, Siebler, J, additional, Schwitulla, J, additional, Wildner, D, additional, Wachter, DL, additional, Neurath, MF, additional, and Strobel, D, additional
- Published
- 2014
- Full Text
- View/download PDF
15. Oncofertility: combination of ovarian stimulation with subsequent ovarian tissue extraction on the day of oocyte retrieval.
- Author
-
Dittrich, R, Lotz, L, Mueller, A, Hoffmann, I, Wachter, DL, Amann, KU, Beckmann, MW, Hildebrandt, T, Dittrich, R, Lotz, L, Mueller, A, Hoffmann, I, Wachter, DL, Amann, KU, Beckmann, MW, and Hildebrandt, T
- Abstract
BACKGROUND: New anticancer treatments have increased survival rates for cancer patients, but often at the cost of sterility. Several strategies are currently available for preserving fertility. However, the chances of achieving a pregnancy with one technique are still limited. A combination of methods is therefore recommended in order to maximize women's chances of future fertility. In this retrospective study, ovarian stimulation with subsequent ovarian tissue extraction on the day of oocyte retrieval were combined and the quality of the ovarian tissue, the numbers and quality of oocytes, time requirements, and the safety of the strategy were examined. METHODS: Fourteen female patients suffering from malignant diseases underwent one in vitro fertilization cycle. Different stimulation protocols were used, depending on the menstrual cycle. Transvaginal oocyte retrieval was scheduled 34-36 h after human chorionic gonadotropin administration. Immediately afterwards, ovarian tissue was extracted laparoscopically. RESULTS: A mean of 10 oocytes were retrieved per patient, and 67% of the oocytes were successfully fertilized using intracytoplasmic sperm injection. No periprocedural complications and no complications leading to postponement of the start of chemotherapy occurred. The ovarian tissues were of good quality, with a normal age-related follicular distribution and without carcinoma cell invasion. CONCLUSIONS: An approach using ovarian stimulation first, followed by laparoscopic collection of ovarian tissue, is a useful strategy for increasing the efficacy of fertility preservation techniques. The ovarian tissue is not affected by prior ovarian stimulation.
- Published
- 2013
16. Einfluss der mammographischen Dichte auf die Prädiktion des Nodalstatus bei Mammakarzinompatientinnen
- Author
-
Hack, CC, primary, Häberle, L, additional, Geisler, K, additional, Schulz-Wendtland, R, additional, Hartmann, A, additional, Fasching, PA, additional, Uder, M, additional, Wachter, DL, additional, Jud, SM, additional, Löhberg, CR, additional, Lux, MP, additional, Rauh, C, additional, Beckmann, MW, additional, and Heusinger, K, additional
- Published
- 2013
- Full Text
- View/download PDF
17. Lokalrezidive nach einer Mammakarzinomerkrankung - Veränderungen der molekularen Charakteristika
- Author
-
Renner, S, primary, Jud, SM, additional, Häberle, L, additional, Hartmann, A, additional, Wachter, DL, additional, Bani, MR, additional, Schulz-Wendtland, R, additional, Lauterbach, B, additional, Beckmann, MW, additional, and Fasching, PA, additional
- Published
- 2013
- Full Text
- View/download PDF
18. Prognostische Relevanz von Ki-67 des Primärtumors in Bezug auf das Gesamtüberleben in der metastasierten Situation beim Mammakarzinom
- Author
-
Löhberg, CR, primary, Almstedt, K, additional, Jud, SM, additional, Häberle, L, additional, Hack, CC, additional, Lux, MP, additional, Thiel, FC, additional, Schrauder, MG, additional, Bayer, CM, additional, Hein, A, additional, Heusinger, K, additional, Heimrich, J, additional, Bani, MR, additional, Renner, S, additional, Beckmann, MW, additional, Hartmann, A, additional, Brunner, M, additional, Wachter, DL, additional, and Fasching, PA, additional
- Published
- 2013
- Full Text
- View/download PDF
19. Zusammenhang zwischen mammographischer Dichte und dem Proliferationsmarker Ki67 bei Patientinnen mit Mammakarzinom
- Author
-
Jud, SM, primary, Heusinger, K, additional, Rauh, C, additional, Häberle, L, additional, Hein, A, additional, Hack, CC, additional, Meier-Meitinger, M, additional, Lux, MP, additional, Schrauder, MG, additional, Wagner, F, additional, Hartmann, A, additional, Wachter, DL, additional, Hagenbeck, C, additional, Uder, M, additional, Beckmann, MW, additional, Löhberg, CR, additional, Fasching, PA, additional, and Schulz-Wendtland, R, additional
- Published
- 2013
- Full Text
- View/download PDF
20. P4-02-07: Influence of the Progesterone Receptor on the Prognosis of Breast Cancer in Interaction with Other Prognostic Factors.
- Author
-
Salmen, JC, primary, Fasching, PA, additional, Hepp, P, additional, Jueckstock, J, additional, Haeberle, L, additional, Mohrmann, S, additional, Beckmann, MW, additional, Hartmann, A, additional, Wachter, DL, additional, Friese, K, additional, Janni, W, additional, and Rack, B, additional
- Published
- 2011
- Full Text
- View/download PDF
21. Interaktion des Progesteronrezeptorstatus mit anderen prognostischen Faktoren beim primären Mammakarzinom
- Author
-
Salmen, J, primary, Hepp, P, additional, Jückstock, J, additional, Wachter, DL, additional, Rack, B, additional, Fasching, PA, additional, Hartmann, A, additional, Beckmann, MW, additional, Janni, W, additional, and Mohrmann, S, additional
- Published
- 2011
- Full Text
- View/download PDF
22. Ki67 zur Vorhersage des Therapieansprechens bei neoadjuvanten Mammakarzinomen
- Author
-
Kahmann, L, primary, Wachter, DL, additional, Heusinger, K, additional, Häberle, L, additional, Hein, A, additional, Bayer, CM, additional, Rauh, C, additional, Schulz-Wendtland, R, additional, Bani, MR, additional, Lux, MP, additional, Strehl, JD, additional, Hartmann, A, additional, Beckmann, MW, additional, and Fasching, PA, additional
- Published
- 2011
- Full Text
- View/download PDF
23. Prädiktive Marker einer pathologischen Komplettremission sind nicht zwangsläufig Prognosefaktoren bei neoadjuvant mit anthrazyklinhaltiger Therapie behandelten Mammakarzinompatientinnen
- Author
-
Rauh, C, primary, Schrauder, MG, additional, Fritsche, A, additional, Koscheck, T, additional, Lux, MP, additional, Bani, MR, additional, Wachter, DL, additional, Hartmann, A, additional, Beckmann, MW, additional, Dimmler, A, additional, and Fasching, PA, additional
- Published
- 2011
- Full Text
- View/download PDF
24. Antitumoröser Effekt von Chloroquin und RAD001 in vitro und in einem Mammakarzinom MCF7 Xenograft Mausmodell
- Author
-
Löhberg, CR, primary, Strissel, P, additional, Strick, R, additional, Polier, A, additional, Fabry, B, additional, Koch, T, additional, Kalender, WA, additional, Dittmer, J, additional, Dittmer, A, additional, Oeser, S, additional, Koppitz, F, additional, Lotz, L, additional, Hoffmann, I, additional, Lux, MP, additional, Fasching, PA, additional, Müller, A, additional, Wachter, DL, additional, Dittrich, R, additional, Beckmann, MW, additional, and Schrauder, MG, additional
- Published
- 2011
- Full Text
- View/download PDF
25. Einfluss von Diabetes mellitus auf die Prognose in einer Brustkrebskohorte
- Author
-
Schrauder, MG, primary, Fasching, PA, additional, Häberle, L, additional, Lux, MP, additional, Rauh, C, additional, Hein, A, additional, Bayer, CM, additional, Heusinger, K, additional, Hartmann, A, additional, Strehl, JD, additional, Wachter, DL, additional, Schulz-Wendtland, R, additional, Adamietz, B, additional, Beckmann, MW, additional, and Löhberg, CR, additional
- Published
- 2011
- Full Text
- View/download PDF
26. Antitumoröser Effekt von Chloroquin und RAD001 in einem Mammakarzinom MCF7 Xenograft Mausmodell
- Author
-
Lotz, L, primary, Hoffmann, I, additional, Loehberg, CR, additional, Schrauder, MG, additional, Müller, A, additional, Polier, A, additional, Kalender, WA, additional, Wachter, DL, additional, Strissel, P, additional, Strick, R, additional, Oeser, S, additional, Koppitz, F, additional, Beckmann, MW, additional, and Dittrich, R, additional
- Published
- 2011
- Full Text
- View/download PDF
27. Assessment of the additional clinical potential of X-ray dark-field imaging for breast cancer in a preclinical setup.
- Author
-
Emons J, Fasching PA, Wunderle M, Heindl F, Rieger J, Horn F, Pelzer G, Ritter A, Weber T, Radicke M, Polifka I, Wachter DL, Wenkel E, Michel T, Uder M, Hartmann A, Anton G, Beckmann MW, Schulz-Wendtland R, and Jud SM
- Abstract
Background: Mammography can identify calcifications up to 50-100 μm in size as a surrogate parameter for breast cancer or ductal carcinoma in situ (DCIS). Microcalcifications measuring <50 µm are also associated with breast cancer or DCIS and are frequently not detected on mammography, although they can be detected with dark-field imaging. This study examined whether additional breast examination using X-ray dark-field imaging can increase the detection rate of calcifications. Advances in knowledge: (1) evaluation of additional modality of breast imaging; (2) specific evaluation of breast calcifications.Implications for patient care: the addition of X-ray dark-field imaging to conventional mammography could detect additional calcifications., Methods: Talbot-Lau X-ray phase-contrast imaging and X-ray dark-field imaging were used to acquire images of breast specimens. The radiation dosage with the technique is comparable with conventional mammography. Three X-ray gratings with periods of 5-10 µm between the X-ray tube and the flat-panel detector provide three different images in a single sequence: the conventional attenuation image, differential phase image, and dark-field image. The images were read by radiologists. Radiological findings were marked and examined pathologically. The results were described in a descriptive manner., Results: A total of 81 breast specimens were investigated with the two methods; 199 significant structures were processed pathologically, consisting of 123 benign and 76 malignant lesions (DCIS or invasive breast cancer). X-ray dark-field imaging identified 15 additional histologically confirmed carcinoma lesions that were visible but not declared suspicious on digital mammography alone. Another four malignant lesions that were not visible on mammography were exclusively detected with X-ray dark-field imaging., Conclusions: Adding X-ray dark-field imaging to digital mammography increases the detection rate for breast cancer and DCIS associated lesions with micrometer-sized calcifications.The use of X-ray dark-field imaging may be able to provide more accurate and detailed radiological classification of suspicious breast lesions.Adding X-ray dark-field imaging to mammography may be able to increase the detection rate and improve preoperative planning in deciding between mastectomy or breast-conserving therapy, particularly in patients with invasive lobular breast cancer., Competing Interests: Conflict of interest statement: MR is an employee of Siemens Healthcare GmbH, Erlangen, Germany. All other authors declare that they do not have any conflicts of interest., (© The Author(s), 2020.)
- Published
- 2020
- Full Text
- View/download PDF
28. Characterization of Molecular Subtypes of Paget Disease of the Breast Using Immunohistochemistry and In Situ Hybridization.
- Author
-
Wachter DL, Wachter PW, Fasching PA, Beckmann MW, Hack CC, Riener MO, Hartmann A, and Strehl JD
- Subjects
- Adult, Aged, Aged, 80 and over, Female, Humans, Immunohistochemistry methods, In Situ Hybridization methods, Male, Middle Aged, Receptor, ErbB-2 analysis, Receptors, Estrogen analysis, Receptors, Progesterone analysis, Biomarkers, Tumor analysis, Breast Neoplasms pathology, Paget's Disease, Mammary pathology
- Abstract
Context.—: Paget disease of the breast, in most cases, represents intraepidermal spread of ductal carcinoma in situ. Molecular subtypes of invasive carcinoma of the breast have prognostic and therapeutic significance and show characteristic distribution. Little is known about the distribution of molecular subtypes in Paget disease of the breast., Objectives.—: To examine the distribution of molecular subtypes in Paget disease of the breast and to compare them to concurrent invasive carcinoma of the breast, if present., Design.—: We examined 48 cases of Paget disease of the breast with immunohistochemistry and antibodies against estrogen and progesterone receptors, human epidermal growth factor receptor 2 (HER2), and Ki-67, as well as HER2 chromogenic in situ hybridization, to classify the cases into molecular subtypes. Then, we compared the results to the molecular subtypes of associated invasive carcinoma of the breast, if present., Results.—: The HER2 subtype was the most common found in Paget disease of the breast, followed by the luminal B subtype and 2 cases of the triple-negative subtype. The associated invasive carcinoma cases were most often of the luminal B subtype, followed by the HER2 subtype and the triple-negative subtype. The molecular subtype of Paget disease and invasive carcinoma was congruent in most of the cases., Conclusions.—: Molecular subtypes of invasive carcinoma of the breast can already be detected in Paget disease. The distribution of molecular subtypes of Paget disease and of Paget disease-associated invasive carcinoma differs from invasive carcinoma without associated Paget disease, with the HER2 subtype overrepresented in Paget disease and associated invasive carcinoma and the luminal and triple-negative subtypes underrepresented.
- Published
- 2019
- Full Text
- View/download PDF
29. The importance of pancreatic inflammation in endosonographic diagnostics of solid pancreatic masses.
- Author
-
Vitali F, Strobel D, Frulloni L, Heinrich M, Pfeifer L, Goertz RS, Hundorfean G, Wachter DL, Gruetzmann R, Bernatik T, Neurath MF, and Wildner D
- Subjects
- Adult, Aged, Aged, 80 and over, Diagnosis, Differential, Female, Humans, Inflammation physiopathology, Male, Middle Aged, Pancreas diagnostic imaging, Pancreas physiopathology, Pancreatic Neoplasms physiopathology, Prospective Studies, Reproducibility of Results, Retrospective Studies, Sensitivity and Specificity, Young Adult, Endosonography methods, Inflammation diagnostic imaging, Pancreatic Neoplasms diagnostic imaging
- Abstract
Aims: Endosonography (EUS) is one of the main diagnostic tools for the differential diagnosis of pancreatic masses. The aim of our study was to describe the value of this technique in the work-up of solid pancreatic lesions, considering the influence of the morphological evidence of pancreatic inflammation in the diagnostic process., Material and Methods: Retrospective analysis of prospectively collected data in our tertiary University center. From March 2007 to October 2015, 218 patients underwent EUS for a suspected solid pancreatic neoplasm (based on previous cross-sectional imaging results, idiopatic acute pancreatitis, weight loss, pancreatic hyperenzymemia, painless jaundice or elevated Ca 19-9 values)., Results: Malignant lesions were diagnosed in 98 (45%) patients. Sensitivity of EUS for malignancy was 91% and specificity 89.2%. Signs of pancreatic inflammation in the surrounding pancreatic parenchyma around the focal lesion were present in 97 patients (44.4%)(more often in men, smokers and drinkers, and the most common etiology was focal chronic pancreatitis) and in these patients the sensitivity and sensibility dropped to 44% and 87.1%, respectively. In patients without signs of pancreatic inflammation, the pancreatic focal lesions were adenocarcinoma, neuroendocrine tumor, ventral/dorsal split, non-pancreatic pathology, pancreatic lipomatosis and autoimmune pancreatitis., Conclusion: Pancreatic inflammation (either focal or involving the whole gland) lowers the diagnostic sensibility of EUS in the work- up of pancreatic masses suspected for cancer, requiring further invasive diagnostic methods. Focal autoimmune pancreatitis and paraduodenal pancreatitis are still confused with pancreatic cancer, even in the absence of pancreatic inflammation.
- Published
- 2018
- Full Text
- View/download PDF
30. Prediction of pathological complete response and prognosis in patients with neoadjuvant treatment for triple-negative breast cancer.
- Author
-
Gass P, Lux MP, Rauh C, Hein A, Bani MR, Fiessler C, Hartmann A, Häberle L, Pretscher J, Erber R, Wachter DL, Schulz-Wendtland R, Beckmann MW, Fasching PA, and Wunderle M
- Subjects
- Adult, Aged, Female, Humans, Kaplan-Meier Estimate, Middle Aged, Neoadjuvant Therapy, Neoplasm Grading, Neoplasm Staging, Odds Ratio, Prognosis, Retrospective Studies, Treatment Outcome, Triple Negative Breast Neoplasms therapy, Triple Negative Breast Neoplasms mortality, Triple Negative Breast Neoplasms pathology
- Abstract
Background: It has been reported that pathological complete response is an important surrogate marker for disease-free survival and overall survival in patients with triple-negative breast cancer. This study investigates predictors of the response to neoadjuvant platinum-based or anthracycline-based treatment, and of the prognosis, in patients with triple-negative breast cancer., Methods: A total of 121 patients with triple-negative breast cancer received neoadjuvant treatment with either platinum or anthracycline between 2008 and 2013. Pathological complete response was assessed relative to different treatments using logistic regression models with age, clinical tumor stage, grading, and Ki-67 as predictors and interaction terms, to obtain adjusted and subgroup-specific results. The impact of the pathological complete response rate on disease-free survival and overall survival was also analyzed., Results: The pathological complete response rate was higher after platinum/taxane treatment compared with anthracycline/taxane (50.0% vs. 41.8%), but this was not significant in the adjusted analysis (OR 1.44; 95% CI, 0.68 to 3.09). A high histological grade (G3) was a predictor for higher pathological complete response in platinum-based therapy (OR 2.27; 95% CI, 1.00 to 5.30). The effect of neoadjuvant chemotherapy on pathological complete response was significantly different for G1-2 vs. G3 (P
interaction = 0.013), and additional subgroup-specific differences were noted. Pathological complete response was a predictor for improved disease-free survival and overall survival in both treatment groups, with and without platinum chemotherapy., Conclusions: This retrospective study of patients with triple-negative breast cancer adds to the evidence that the treatment effect of platinum may be greatest particularly in G3 tumors. In addition, the effect of pathological complete response on the prognosis does not depend on the treatment used.- Published
- 2018
- Full Text
- View/download PDF
31. Expression and Regulation of Retinoic Acid Receptor Responders in the Human Placenta.
- Author
-
Huebner H, Hartner A, Rascher W, Strick RR, Kehl S, Heindl F, Wachter DL, Beckmann Md MW, Fahlbusch FB, and Ruebner M
- Subjects
- Cell Line, DNA Methylation, Female, Fetal Growth Retardation genetics, Gene Expression Regulation, Humans, Pre-Eclampsia genetics, Pre-Eclampsia metabolism, Pregnancy, Promoter Regions, Genetic, Receptors, Retinoic Acid genetics, Trophoblasts metabolism, Up-Regulation, Fetal Growth Retardation metabolism, Placenta metabolism, Receptors, Retinoic Acid metabolism
- Abstract
Introduction: Retinoic acid (RA) signaling through its receptors (RARA, RARB, RARG, and the retinoic X receptor RXRA) is essential for healthy placental and fetal development. An important group of genes regulated by RA are the RA receptor responders (RARRES1, 2, and 3). We set out to analyze their expression and regulation in healthy and pathologically altered placentas of preeclampsia (PE) and intrauterine growth restriction (IUGR) as well as in trophoblast cell lines., Methods: We performed immunohistochemical staining on placental sections and analyzed gene expression by real-time polymerase chain reaction. Additionally, we performed cell culture experiments and stimulated Swan71 and Jeg-3 cells with different RA derivates and 2'-deoxy-5-azacytidine (AZA) to induce DNA demethylation., Results: RARRES1, 2, and 3 and RARA, RARB, RARG, and RXRA are expressed in the extravillous part of the placenta. RARRES1, RARA, RARG, and RXRA were additionally detected in villous cytotrophoblasts. RARRES gene expression was induced via activation of RARA, RARB, and RARG in trophoblast cells. RARRES1 was overexpressed in villous trophoblasts and the syncytiotrophoblast from PE placentas, but not in IUGR without PE. Promoter methylation was detectable for RARRES1 and RARB based on their sensitivity toward AZA treatment of trophoblast cell lines., Discussion: RARRES1, 2 and 3 are expressed in the functional compartments of the human placenta and can be regulated by RA. We hypothesize that the epigenetic suppression of trophoblast RARRES1 and RARB expression and the upregulation of RARRES1 in PE trophoblast cells suggest an involvement of environmental factors (eg, maternal vitamin A intake) in the pathogenesis of this pregnancy complication.
- Published
- 2018
- Full Text
- View/download PDF
32. In-situ analysis of mast cells and dendritic cells in coronary atherosclerosis in chronic kidney disease (CKD).
- Author
-
Wachter DL, Neureiter D, Câmpean V, Hilgers KF, Büttner-Herold M, Daniel C, Benz K, and Amann K
- Subjects
- Aged, B-Lymphocytes immunology, B-Lymphocytes pathology, Case-Control Studies, Coronary Artery Disease complications, Coronary Artery Disease immunology, Coronary Vessels immunology, Dendritic Cells immunology, Female, Humans, Inflammation Mediators analysis, Macrophages immunology, Macrophages pathology, Male, Mast Cells immunology, Middle Aged, Renal Insufficiency, Chronic diagnosis, Severity of Illness Index, T-Lymphocytes immunology, T-Lymphocytes pathology, Vascular Calcification pathology, Coronary Artery Disease pathology, Coronary Vessels pathology, Dendritic Cells pathology, Mast Cells pathology, Plaque, Atherosclerotic, Renal Insufficiency, Chronic complications
- Abstract
Aims: Mast cells (MC) and dendritic cells (DC) have immune modulatory function and can influence T-cell activity. Both cell types have been found in atherosclerotic plaques and are thought to play an important role for plaque stability. Compared to matched segments of the non-renal population, patients with chronic kidney disease (CKD) show a more pronounced and more aggressive course of atherosclerosis with higher plaque calcification and significantly higher complications rates. It was the aim of this study to analyze the number and localization of MCs and DCs, macrophages, T- and B-cells as well as the expression of markers of inflammation such as CRP and NFκB in calcified and non-calcified atherosclerotic plaques of patients with CKD and control patients., Methods: Fifty coronary atherosclerotic plaques from patients with endstage CKD (CKD, n=25) and control (n=25) patients were categorized according to the Stary classification and investigated using immunohistochemistry (markers for MC, DC, T, B, macrophage and NFκB). Expression was analyzed separately for the complete plaque area as well as for the different plaque subregions and correlations were analyzed., Results: We found only very few DCs and MCs per lesion area with slightly increased numbers in calcified plaques. MCs per plaque area were significantly more frequent in CKD than in control patients and this was independent of plaque calcification. MCs were most frequently found in the shoulder and basis of the plaque. DCs per plaque area were significantly less in calcified plaques of CKD compared to control patients. In control, but not in CKD patients, DCs were significantly more frequent in calcified than in non-calcified plaques. Within the plaques DCs were similarly distributed between all 4 subregions., Conclusions: Coronary atherosclerotic plaques of CKD patients showed a significantly higher number of MCs whereas DCs were less frequent compared to control patients particularly if plaques were calcified. These findings might indicate a potential proinflammatory role of MCs, but not of DCs in atherosclerotic lesions of CKD patients, adding another characteristic of advanced atherosclerosis in these patients.
- Published
- 2018
- Full Text
- View/download PDF
33. Detyrosinated tubulin is decreased in fetal vessels of preeclampsia placentas.
- Author
-
Huebner H, Knoerr B, Betzler A, Hartner A, Kehl S, Baier F, Wachter DL, Strick R, Beckmann MW, Fahlbusch FB, and Ruebner M
- Subjects
- Chorionic Villi metabolism, Endothelial Cells metabolism, Female, Humans, Infant, Small for Gestational Age, Microtubules metabolism, Pregnancy, Stromal Cells metabolism, Placenta metabolism, Pre-Eclampsia metabolism, Protein Processing, Post-Translational physiology, Tubulin metabolism, Tyrosine metabolism
- Abstract
Introduction: Preeclampsia is a hypertensive, gestational disease, which is still the leading cause of pregnancy related morbidity and mortality. The impairment of placental angiogenesis and vascularization is discussed to be of etiopathologic relevance. Deytrosination and tyrosination of α-tubulin is important for the stability and dynamics of microtubules. An increase of α-tubulin detyrosination leads to microtubule stabilization, which is an essential prerequisite for physiologic vascular tube morphogenesis during angiogenesis. So far, little is known about the specific localization of detyrosinated (detyr) and tyrosinated (tyr) tubulin in the placenta and its relevance for preeclampsia., Methods: Placental expression of detyr- and tyr-tubulin was analyzed by immunohistochemistry, immunofluorescence and western blot. For western blot quantification we used biopsies from healthy placentas (n = 21) and placentas from pregnancies complicated with small for gestational age (n = 5), preeclampsia (n = 5) or both (n = 5)., Results: Specific placental localization of detyr-tubulin was detected in the fetal endothelial cells of the placenta. Villous and extravillous trophoblasts as well as villous stroma cells were tyr-tubulin positive. Detyr-tubulin protein expression was significantly decreased in placentas complicated by preeclampsia., Conclusions: In summary, we report an accumulation of detyr-tubulin in villous vessels of the placenta and a significantly reduced level of detyr-tubulin in placental biopsies of preeclampsia cases. The reduction of placental detyr-tubulin in preeclampsia could suggest a deficit in villous vascular plasticity and might be associated with the impaired arborization of the disease., (Copyright © 2018 Elsevier Ltd. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
34. Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer.
- Author
-
Goode EL, Block MS, Kalli KR, Vierkant RA, Chen W, Fogarty ZC, Gentry-Maharaj A, Tołoczko A, Hein A, Bouligny AL, Jensen A, Osorio A, Hartkopf A, Ryan A, Chudecka-Głaz A, Magliocco AM, Hartmann A, Jung AY, Gao B, Hernandez BY, Fridley BL, McCauley BM, Kennedy CJ, Wang C, Karpinskyj C, de Sousa CB, Tiezzi DG, Wachter DL, Herpel E, Taran FA, Modugno F, Nelson G, Lubiński J, Menkiszak J, Alsop J, Lester J, García-Donas J, Nation J, Hung, Palacios J, Rothstein JH, Kelley JL, de Andrade JM, Robles-Díaz L, Intermaggio MP, Widschwendter M, Beckmann MW, Ruebner M, Jimenez-Linan M, Singh N, Oszurek O, Harnett PR, Rambau PF, Sinn P, Wagner P, Ghatage P, Sharma R, Edwards RP, Ness RB, Orsulic S, Brucker SY, Johnatty SE, Longacre TA, Ursula E, McGuire V, Sieh W, Natanzon Y, Li Z, Whittemore AS, Anna A, Staebler A, Karlan BY, Gilks B, Bowtell DD, Høgdall E, Candido dos Reis FJ, Steed H, Campbell IG, Gronwald J, Benítez J, Koziak JM, Chang-Claude J, Moysich KB, Kelemen LE, Cook LS, Goodman MT, García MJ, Fasching PA, Kommoss S, Deen S, Kjaer SK, Menon U, Brenton JD, Pharoah PDP, Chenevix-Trench G, Huntsman DG, Winham SJ, Köbel M, and Ramus SJ
- Subjects
- BRCA2 Protein genetics, Carcinoma, Ovarian Epithelial immunology, Carcinoma, Ovarian Epithelial pathology, Cohort Studies, Cystadenocarcinoma, Serous genetics, Cystadenocarcinoma, Serous pathology, Female, Humans, Middle Aged, Mutation, Neoplasm Grading, Ovarian Neoplasms genetics, Ovarian Neoplasms pathology, Prospective Studies, Survival Analysis, Treatment Outcome, CD8 Antigens metabolism, Carcinoma, Ovarian Epithelial drug therapy, Cystadenocarcinoma, Serous immunology, Lymphocytes, Tumor-Infiltrating immunology, Ovarian Neoplasms immunology
- Abstract
Importance: Cytotoxic CD8+ tumor-infiltrating lymphocytes (TILs) participate in immune control of epithelial ovarian cancer; however, little is known about prognostic patterns of CD8+ TILs by histotype and in relation to other clinical factors., Objective: To define the prognostic role of CD8+ TILs in epithelial ovarian cancer., Design, Setting, and Participants: This was a multicenter observational, prospective survival cohort study of the Ovarian Tumor Tissue Analysis Consortium. More than 5500 patients, including 3196 with high-grade serous ovarian carcinomas (HGSOCs), were followed prospectively for over 24 650 person-years., Exposures: Following immunohistochemical analysis, CD8+ TILs were identified within the epithelial components of tumor islets. Patients were grouped based on the estimated number of CD8+ TILs per high-powered field: negative (none), low (1-2), moderate (3-19), and high (≥20). CD8+ TILs in a subset of patients were also assessed in a quantitative, uncategorized manner, and the functional form of associations with survival was assessed using penalized B-splines., Main Outcomes and Measures: Overall survival time., Results: The final sample included 5577 women; mean age at diagnosis was 58.4 years (median, 58.2 years). Among the 5 major invasive histotypes, HGSOCs showed the most infiltration. CD8+ TILs in HGSOCs were significantly associated with longer overall survival; median survival was 2.8 years for patients with no CD8+ TILs and 3.0 years, 3.8 years, and 5.1 years for patients with low, moderate, or high levels of CD8+ TILs, respectively (P value for trend = 4.2 × 10−16). A survival benefit was also observed among women with endometrioid and mucinous carcinomas, but not for those with the other histotypes. Among HGSOCs, CD8+ TILs were favorable regardless of extent of residual disease following cytoreduction, known standard treatment, and germline BRCA1 pathogenic mutation, but were not prognostic for BRCA2 mutation carriers. Evaluation of uncategorized CD8+ TIL counts showed a near-log-linear functional form., Conclusions and Relevance: This study demonstrates the histotype-specific nature of immune infiltration and provides definitive evidence for a dose-response relationship between CD8+ TILs and HGSOC survival. That the extent of infiltration is prognostic, not merely its presence or absence, suggests that understanding factors that drive infiltration will be the key to unraveling outcome heterogeneity in this cancer.
- Published
- 2017
- Full Text
- View/download PDF
35. Hypermethylation and loss of retinoic acid receptor responder 1 expression in human choriocarcinoma.
- Author
-
Huebner H, Strick R, Wachter DL, Kehl S, Strissel PL, Schneider-Stock R, Hartner A, Rascher W, Horn LC, Beckmann MW, Ruebner M, and Fahlbusch FB
- Subjects
- Cell Line, Tumor, Choriocarcinoma metabolism, Disease Progression, Epigenesis, Genetic, Female, Gene Expression Regulation, Neoplastic, Humans, Membrane Proteins metabolism, Pregnancy, Promoter Regions, Genetic, Sequence Analysis, DNA, Uterine Neoplasms metabolism, Choriocarcinoma genetics, DNA Methylation, Down-Regulation, Membrane Proteins genetics, Uterine Neoplasms genetics
- Abstract
Background: Human placental development resembles tumorigenesis, due to the invasive and fusogenic potential of trophoblasts. However, these features are tightly controlled in trophoblasts. Disturbance of this spatial and temporal regulation is thought to contribute to the rare formation of choriocarcinomas. Promoter hypermethylation and loss of the tumor suppressor Retinoic acid receptor responder 1 (RARRES1) were shown to contribute to cancer progression. Our study investigated the epigenetic and transcriptional regulation of RARRES1 in healthy human placenta in comparison to choriocarcinoma cell lines and cases., Methods: Three choriocarcinoma cell lines (Jeg-3, JAR and BeWo) were treated with three different retinoic acid derivates (Am580, Tazarotene and all-trans retinoic acid) and 5-aza-2'-deoxycytidine. We analyzed RARRES1 promoter methylation by pyrosequencing and performed realtime-PCR quantification to determine RARRES1 expression in placental tissue and trophoblastic cell lines. Additionally, RARRES1 was stained in healthy placentas and in biopsies of choriocarcinoma cases (n = 10) as well as the first trimester trophoblast cell line Swan71 by immunofluorescence and immunohistochemistry., Results: In the choriocarcinoma cell lines, RARRES1 expression could not be induced by sole retinoic acid treatment. Stimulation with 5-aza-2'-deoxycytidine significantly induced RARRES1 expression, which then could be further increased with Am580, Tazarotene and all-trans retinoic acid. In comparison to healthy placenta, choriocarcinoma cell lines showed a hypermethylation of the RARRES1 promoter, which correlated with a reduced RARRES1 expression. In concordance, RARRES1 protein expression was lost in choriocarcinoma tissue. Additionally, in the trophoblastic cell line Swan71, we found a significant induction of RARRES1 expression with increased cell density, during mitosis and in syncytial knots., Conclusions: Our findings showed that RARRES1 expression is absent in choriocarcinoma due to promoter methylation. Based on our analysis, we hypothesize that RARRES1 might exert tumor suppressive functions in multiple cellular processes (e.g. cell cycle regulation, adhesion, invasion and apoptosis).
- Published
- 2017
- Full Text
- View/download PDF
36. [New prognostic and predictive markers for breast cancer].
- Author
-
Wachter DL
- Subjects
- Breast Neoplasms classification, Female, Humans, Immunohistochemistry, Ki-67 Antigen genetics, Neuroendocrine Tumors classification, Prognosis, Biomarkers, Tumor genetics, Breast pathology, Breast Neoplasms genetics, Breast Neoplasms pathology, Cell Transformation, Neoplastic genetics, Cell Transformation, Neoplastic pathology, Neuroendocrine Tumors genetics, Neuroendocrine Tumors pathology
- Abstract
Breast cancer can be divided into four molecular subtypes with different prognoses using immunohistochemical markers in the routine clinicopathological work-up. The protein Ki-67 is of central importance in this context, in particular to distinguish between luminal A and luminal B carcinomas. Determination of the Ki-67 index of a carcinoma also allows a prediction of the likelihood of the response to chemotherapy. Additionally, the expression of certain cytokeratins in tumor cells is associated with a poor response to chemotherapy. The heterogeneity of molecular subtypes with regard to the histological appearance indicates an even greater diversity of breast cancer. We were able to show that a high proportion of luminal B carcinomas display neuroendocrine differentiation. Further studies with particular emphasis on histomorphological criteria should be performed to attain a more accurate classification of breast cancer and to pave the way towards targeted therapies for a better prognosis in the future.
- Published
- 2016
- Full Text
- View/download PDF
37. Virilizing Hilus Cell Tumor of the Ovary Associated With Efferent Ductules-like Metaplasia Within Paratubal Mesonephric Remnants.
- Author
-
Wachter DL, Burghaus S, Beckmann MW, and Agaimy A
- Subjects
- Aged, Epithelium pathology, Female, Humans, Leydig Cell Tumor complications, Ovarian Neoplasms complications, Ovary pathology, Leydig Cell Tumor pathology, Metaplasia pathology, Ovarian Neoplasms pathology, Virilism etiology
- Published
- 2016
- Full Text
- View/download PDF
38. DNA methylation outliers in normal breast tissue identify field defects that are enriched in cancer.
- Author
-
Teschendorff AE, Gao Y, Jones A, Ruebner M, Beckmann MW, Wachter DL, Fasching PA, and Widschwendter M
- Subjects
- Adult, Breast Neoplasms metabolism, Case-Control Studies, Cohort Studies, Epigenomics, Female, Gene Regulatory Networks, Humans, Breast Neoplasms genetics, DNA Methylation
- Abstract
Identifying molecular alterations in normal tissue adjacent to cancer is important for understanding cancer aetiology and designing preventive measures. Here we analyse the DNA methylome of 569 breast tissue samples, including 50 from cancer-free women and 84 from matched normal cancer pairs. We use statistical algorithms for dissecting intra- and inter-sample cellular heterogeneity and demonstrate that normal tissue adjacent to breast cancer is characterized by tens to thousands of epigenetic alterations. We show that their genomic distribution is non-random, being strongly enriched for binding sites of transcription factors specifying chromatin architecture. We validate the field defects in an independent cohort and demonstrate that over 30% of the alterations exhibit increased enrichment within matched cancer samples. Breast cancers highly enriched for epigenetic field defects, exhibit adverse clinical outcome. Our data support a model where clonal epigenetic reprogramming towards reduced differentiation in normal tissue is an important step in breast carcinogenesis.
- Published
- 2016
- Full Text
- View/download PDF
39. Touch Imprint Cytology and Stereotactically-Guided Core Needle Biopsy of Suspicious Breast Lesions: 15-Year Follow-up.
- Author
-
Schulz-Wendtland R, Fasching PA, Bani MR, Lux MP, Jud S, Rauh C, Bayer C, Wachter DL, Hartmann A, Beckmann MW, Uder M, and Loehberg CR
- Abstract
Introduction: Stereotactically-guided core needle biopsies (CNB) of breast tumours allow histological examination of the tumour without surgery. Touch imprint cytology (TIC) of CNB promises to be useful in providing same-day diagnosis for counselling purposes and for planning future surgery. Having addressed the issue of accuracy of immediate microscopic evaluation of TIC, we wanted to re-examine the usefulness of this procedure in light of the present health care climate of cost containment by incorporating the surgical 15-year follow-up data and outcome. Patients and Methods: From January until December 1996 we performed TIC in core needle biopsies of 173 breast tumours in 169 patients, consisting of 122 malignant and 51 benign tumours. Histology of core needle biopsies was proven by surgical histology in all malignant and in 5 benign tumours. Surgical breast biopsy was not performed in 46 patients with 46 benign lesions, as the histological result from the core needle biopsy and the result of the TIC were in agreement with the suspected diagnosis from the complementary breast diagnostics. A 15-year follow-up of these patients followed in 2013 and follow-up data was collected from 40 women. Results: In the 15-year follow-up of the 40 benign lesions primarily confirmed using CNB and TIC, a diagnostic sensitivity, specificity, positive and negative predictive value and accuracy of 100 % was found. Conclusion: TIC and stereotactically guided CNB showed excellent long-term follow-up in patients with benign breast lesions. The use of TIC to complement CNB can therefore provide immediate cytological diagnosis of breast lesions.
- Published
- 2016
- Full Text
- View/download PDF
40. Fine needle aspiration cytology of lymph nodes in breast cancer follow-up is a feasible alternative to watchful waiting and to histology.
- Author
-
Hammon M, Dankerl P, Janka R, Wachter DL, Hartmann A, Schulz-Wendtland R, Uder M, and Wenkel E
- Subjects
- Adult, Breast pathology, Breast Neoplasms pathology, Cytodiagnosis standards, Female, Follow-Up Studies, Humans, Lymph Node Excision methods, Lymph Node Excision statistics & numerical data, Lymph Nodes pathology, Middle Aged, Watchful Waiting standards, Biopsy, Fine-Needle methods, Breast Neoplasms diagnosis, Cytodiagnosis methods, Sentinel Lymph Node Biopsy methods
- Abstract
Background: Early detection of loco-regional breast cancer recurrence improves patients' overall survival, as treatment can be initiated or active treatment can be changed. If a suspicious lymph node is diagnosed during a follow-up exam, surgical excision is often performed. The aim of this study was to evaluate the diagnostic performance of the minor invasive ultrasound-guided fine-needle aspiration cytology (FNAC) in sonomorphologically suspicious lymph nodes in breast cancer follow-up., Methods: Between April 2010 and November 2012, we performed ultrasound-guided FNAC in 38 sonographically suspicious lymph nodes of 37 breast cancer follow-up patients. Cytological specimens were evaluated if the sample material was sufficient for diagnosis and if they contained cancer cells. Patients with negative cytology were followed up clinically and sonographically. To evaluate the diagnostic performance we calculated sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) for physical examination, the different sonomorphological malignancy criteria and FNAC., Results: In 36/38 (94.7 %) lymph nodes, the pathologist had enough material to establish a final diagnosis; in 2/38 (5.3 %) lymph nodes, the probe material was non-evaluable during cytology, these 2 were excluded from further statistical evaluation. Cytology revealed malignancy in 21 lymph nodes and showed no evidence for malignancy in 15 lymph nodes. There was no evidence for malignant disease in follow-up exams in the 15 cytologically benign lymph nodes with an average follow-up time of 3 years. The diagnostic performances of physical examination and FNAC were: Sensitivity 52/100 %, specificity 88/100 %, PPV 85/100 %, NPV 60/100 %, respectively., Conclusions: Our preliminary results show that FNAC is a safe and fast diagnostic approach for the evaluation of suspicious lymph nodes in the follow-up of patients with breast cancer and, thus, together with follow-up represents a feasible alternative to surgery.
- Published
- 2015
- Full Text
- View/download PDF
41. Association of molecular subtypes with breast cancer risk factors: a case-only analysis.
- Author
-
Rauh C, Gass P, Heusinger K, Haeberle L, Jud SM, Hein A, Loehberg CR, Lux MP, Wachter DL, Heimrich J, Strehl JD, Haller F, Hartmann A, Schulz-Wendtland R, Fiessler C, Beckmann MW, Fasching PA, and Poehls U
- Subjects
- Adult, Breast Neoplasms metabolism, Female, Humans, Middle Aged, Neoplasm Staging, Prognosis, Risk Factors, Triple Negative Breast Neoplasms metabolism, Breast Neoplasms classification, Breast Neoplasms pathology, Receptor, ErbB-2 metabolism, Receptors, Estrogen metabolism, Receptors, Progesterone metabolism, Triple Negative Breast Neoplasms pathology
- Abstract
As breast cancer (BC) screening identifies many BCs with a good prognosis, which might be overdiagnosed and therefore overtreated, the identification of subgroups with a high risk for aggressive subtypes might be helpful. The aim of this case-case analysis was to investigate the association between epidemiological risk factors and molecular subtypes in a cohort of BC patients. Epidemiological risk factors for 2587 BC patients were obtained using a structured questionnaire and from the patients' charts. The histopathological information (estrogen and progesterone receptor, HER2 and Ki-67) used in the analysis was retrieved from the original pathology reports. Analyses using conditional inference regression trees were carried out on these data. The strongest influence factor on the distribution of the molecular subtypes was age at first diagnosis of BC. An influence of BMI was also identified in patients aged either more than 42 years or 49.6 years or less. Older patients aged more than 49.6 years and perimenopausal women with a BMI of 32.4 kg/m or less were most likely to develop luminal A-like BC. Young patients aged 42 years or less and perimenopausal patients with a BMI more than 32.4 kg/m more often developed triple-negative BC. The study confirmed that age at diagnosis is an important factor influencing the distribution of molecular subtypes. In the perimenopausal group, it may be postulated that BMI plays a critical role in the pathogenesis of BC, defining a subgroup that is more likely to develop triple-negative BC or luminal B-like disease and another group in which there is a more postmenopausal distribution pattern.
- Published
- 2015
- Full Text
- View/download PDF
42. Intraparotid classical and nodular lymphocyte-predominant Hodgkin lymphoma: pattern analysis with emphasis on associated lymphadenoma-like proliferations.
- Author
-
Agaimy A, Wild V, Märkl B, Wachter DL, Hartmann A, Rosenwald A, and Ihrler S
- Subjects
- Adenoma chemistry, Adult, Aged, Aged, 80 and over, Biopsy, Diagnosis, Differential, Epithelial Cells chemistry, Female, Hodgkin Disease metabolism, Humans, Immunohistochemistry, Lymph Nodes chemistry, Lymphocytes chemistry, Lymphoproliferative Disorders metabolism, Male, Middle Aged, Parotid Gland chemistry, Parotid Neoplasms chemistry, Predictive Value of Tests, Prognosis, Adenoma pathology, Cell Proliferation, Epithelial Cells pathology, Hodgkin Disease pathology, Lymph Nodes pathology, Lymphocytes pathology, Lymphoproliferative Disorders pathology, Parotid Gland pathology, Parotid Neoplasms pathology
- Abstract
Most of the lymphoproliferative diseases involving the salivary glands represent indolent non-Hodgkin B-cell lymphoma (marginal zone lymphoma) related to chronic autoimmune sialadenitis (Sjögren disease). Other types of non-Hodgkin lymphomas involve the salivary glands less frequently. On rare occasions, classical Hodgkin lymphoma (CHL) and nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) present initially as a primary salivary gland mass. We analyzed a series of CHL (n=3) and NLPHL (n=6) presenting initially as parotid gland tumors concerning their pattern (parenchymal vs. intraparotid lymph node) and the presence of salivary inclusions and epithelial proliferations within the lymphoma infiltrate. The pattern of infiltration was determined on hematoxylin and eosin-stained slides assisted by immunostaining for pancytokeratin to highlight lobular salivary gland parenchyma. Patients included 6 male and 3 female individuals with a mean age of 62 years (range, 36 to 88 y). Lymphoma was localized within intraparotid lymph nodes in 8 cases and was limited to salivary parenchyma in 1 case. Parenchymal involvement in nodal-based cases was scored as absent (3) or minimal (5). Salivary inclusions (acini and ductules) within affected lymph nodes were noted in 6 cases (4/5 NLPHLs and 2/3 CHLs). In 3/6 NLPHL cases, salivary inclusions showed variable proliferative changes ranging from prominent lymphoepithelial lesions to cystic and oncocytic (Warthin-like) epithelial changes. Scanty small lymphoepithelial lesions were seen in 1 of the 3 CHL cases. One NLPHL in the intraparotid lymph node was accompanied by prominent lymphoepithelial sialadenitis in the absence of clinical signs of Sjögren disease. This study highlights that a majority of parotid gland Hodgkin lymphomas arise within intraparotid lymph nodes. Frequent entrapment and proliferation of salivary ducts and acini within the lymphoma infiltrate might mimic a variety of benign lymphoepithelial mass-forming lesions (nonsebaceous lymphadenoma, Warthin tumor, and autoimmune sialadenitis). Pancytokeratin stain is helpful for reliable assessment of the background architecture.
- Published
- 2015
- Full Text
- View/download PDF
43. Pattern of SMARCB1 (INI1) and SMARCA4 (BRG1) in poorly differentiated endometrioid adenocarcinoma of the uterus: analysis of a series with emphasis on a novel SMARCA4-deficient dedifferentiated rhabdoid variant.
- Author
-
Strehl JD, Wachter DL, Fiedler J, Heimerl E, Beckmann MW, Hartmann A, and Agaimy A
- Subjects
- Aged, Aged, 80 and over, Carcinoma, Endometrioid genetics, Carcinoma, Endometrioid pathology, Cell Differentiation physiology, Endometrial Neoplasms genetics, Endometrial Neoplasms pathology, Female, Humans, Immunohistochemistry, Middle Aged, Phenotype, Rhabdoid Tumor genetics, Rhabdoid Tumor pathology, SMARCB1 Protein, Biomarkers, Tumor metabolism, Carcinoma, Endometrioid metabolism, Chromosomal Proteins, Non-Histone metabolism, DNA Helicases metabolism, DNA-Binding Proteins metabolism, Endometrial Neoplasms metabolism, Nuclear Proteins metabolism, Rhabdoid Tumor metabolism, Transcription Factors metabolism
- Abstract
The role of the switch/sucrose nonfermenting chromatin remodeling complex in the initiation and progression of cancer is emerging. In the female genital tract, only ovarian small cell carcinoma, hypercalcemic type harbors recurrent inactivating SMARCA4 mutations. Otherwise, only rare case reports documented SMARCB1 involvement in endometrial cancer. We analyzed 24 grade 3 uterine endometrioid adenocarcinomas and 2 undifferentiated carcinomas for immunohistochemical expression of SMARCB1 and SMARCA4. All tumors showed high-grade nuclear features with a predominance of solid growth pattern. All cases showed intact nuclear SMARCB1 expression in all tumor cells. However, 1 case of a 78-year-old woman showed complete loss of SMARCA4 in 90% of the tumor with retained expression in 10% of the tumor. The SMARCA4-intact component was a moderate-to-poorly differentiated endometrioid adenocarcinoma. The SMARCA4-deficient dominating component showed solid growth of highly anaplastic undifferentiated large cells with prominent rhabdoid features. None of the 25 SMARCA4-intact cases showed rhabdoid cell morphology. To our knowledge, this is the first systematic study of SMARCB1 and SMARCA4 expression in endometrioid adenocarcinoma of uterus and the first description of a novel SMARCA4-deficient variant of dedifferentiated/undifferentiated endometrial carcinoma. The presence of a differentiated SMARCA4-intact endometrioid component points to a novel pathway of dedifferentiation in endometrioid adenocarcinoma as a consequence of a "second hit." This case further underlines the close link between the "rhabdoid phenotype" and the SWI/SNF pathway., (Copyright © 2015 Elsevier Inc. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
44. Mesothelial/monocytic incidental cardiac excrescences (cardiac MICE) associated with acute aortic dissection: a study of two cases.
- Author
-
Strecker T, Bertz S, Wachter DL, Weyand M, and Agaimy A
- Subjects
- Aged, Aortic Dissection diagnostic imaging, Aortic Aneurysm diagnostic imaging, Female, Heart diagnostic imaging, Humans, Male, Middle Aged, Radiography, Aortic Dissection pathology, Aortic Aneurysm pathology, Histiocytes pathology, Monocytes pathology, Myocardium pathology
- Abstract
Acute aortic dissection is a life-threatening condition mainly caused by hypertension, atherosclerotic disease and other degenerative diseases of the connective tissue of the aortic wall. Mesothelial/monocytic incidental cardiac excrescences (cardiac MICE) is a rare benign reactive tumor-like lesion composed of admixture of histiocytes, mesothelial cells, and inflammatory cells set within a fibrinous meshwork without a vascular network or supporting stroma. Cardiac MICE occurring in association with aortic dissection is exceptionally rare (only one such case reported to date). We herein report on the surgical repair of two Stanford type A aortic dissections caused by idiopathic giant cell aortitis in a 66-year-old-woman and by atherosclerotic disease in a 58-year-old-man, respectively. In both cases, the dissections could be visualized via computed tomography. Histopathology showed cardiac incidental MICE within the external aortic wall near the pericardial surface which was confirmed by immunohistochemistry.
- Published
- 2015
45. Comparison of Sonography versus Digital Breast Tomosynthesis to Locate Intramammary Marker Clips.
- Author
-
Schulz-Wendtland R, Dankerl P, Dilbat G, Bani M, Fasching PA, Heusinger K, Lux MP, Loehberg CR, Jud SM, Rauh C, Bayer CM, Beckmann MW, Wachter DL, Uder M, Meier-Meitinger M, and Brehm B
- Abstract
Introduction: This study aimed to compare the accuracy of sonography versus digital breast tomosynthesis to locate intramammary marker clips placed under ultrasound guidance. Patients and Methods: Fifty patients with suspicion of breast cancer (lesion diameter less than 2 cm [cT1]) had ultrasound-guided core needle biopsy with placement of a marker clip in the center of the tumor. Intramammary marker clips were subsequently located with both sonography and digital breast tomosynthesis. Results: Sonography detected no dislocation of intrammammary marker clips in 42 of 50 patients (84 %); dislocation was reported in 8 patients (16 %) with a maximum dislocation of 7 mm along the x-, y- or z-axis. Digital breast tomosynthesis showed accurate placement without dislocation of the intramammary marker clip in 48 patients (96 %); 2 patients (4 %) had a maximum clip dislocation of 3 mm along the x-, y- or z-axis (p < 0.05). Conclusion: The use of digital breast tomosynthesis could improve the accuracy when locating intramammary marker clips compared to sonography and could, in future, be used to complement or even completely replace sonography.
- Published
- 2015
- Full Text
- View/download PDF
46. Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study.
- Author
-
Köbel M, Madore J, Ramus SJ, Clarke BA, Pharoah PD, Deen S, Bowtell DD, Odunsi K, Menon U, Morrison C, Lele S, Bshara W, Sucheston L, Beckmann MW, Hein A, Thiel FC, Hartmann A, Wachter DL, Anglesio MS, Høgdall E, Jensen A, Høgdall C, Kalli KR, Fridley BL, Keeney GL, Fogarty ZC, Vierkant RA, Liu S, Cho S, Nelson G, Ghatage P, Gentry-Maharaj A, Gayther SA, Benjamin E, Widschwendter M, Intermaggio MP, Rosen B, Bernardini MQ, Mackay H, Oza A, Shaw P, Jimenez-Linan M, Driver KE, Alsop J, Mack M, Koziak JM, Steed H, Ewanowich C, DeFazio A, Chenevix-Trench G, Fereday S, Gao B, Johnatty SE, George J, Galletta L, Goode EL, Kjær SK, Huntsman DG, Fasching PA, Moysich KB, Brenton JD, and Kelemen LE
- Subjects
- Carcinoma, Ovarian Epithelial, Disease-Free Survival, Female, Humans, Immunohistochemistry, Middle Aged, Survival Analysis, Tissue Array Analysis, Biomarkers, Tumor biosynthesis, Folate Receptor 1 biosynthesis, Neoplasms, Glandular and Epithelial metabolism, Ovarian Neoplasms metabolism
- Abstract
Background: Folate receptor 1 (FOLR1) is expressed in the majority of ovarian carcinomas (OvCa), making it an attractive target for therapy. However, clinical trials testing anti-FOLR1 therapies in OvCa show mixed results and require better understanding of the prognostic relevance of FOLR1 expression. We conducted a large study evaluating FOLR1 expression with survival in different histological types of OvCa., Methods: Tissue microarrays composed of tumour samples from 2801 patients in the Ovarian Tumour Tissue Analysis (OTTA) consortium were assessed for FOLR1 expression by centralised immunohistochemistry. We estimated associations for overall (OS) and progression-free (PFS) survival using adjusted Cox regression models. High-grade serous ovarian carcinomas (HGSC) from The Cancer Genome Atlas (TCGA) were evaluated independently for association between FOLR1 mRNA upregulation and survival., Results: FOLR1 expression ranged from 76% in HGSC to 11% in mucinous carcinomas in OTTA. For HGSC, the association between FOLR1 expression and OS changed significantly during the years following diagnosis in OTTA (Pinteraction=0.01, N=1422) and TCGA (Pinteraction=0.01, N=485). In OTTA, particularly for FIGO stage I/II tumours, patients with FOLR1-positive HGSC showed increased OS during the first 2 years only (hazard ratio=0.44, 95% confidence interval=0.20-0.96) and patients with FOLR1-positive clear cell carcinomas (CCC) showed decreased PFS independent of follow-up time (HR=1.89, 95% CI=1.10-3.25, N=259). In TCGA, FOLR1 mRNA upregulation in HGSC was also associated with increased OS during the first 2 years following diagnosis irrespective of tumour stage (HR: 0.48, 95% CI: 0.25-0.94)., Conclusions: FOLR1-positive HGSC tumours were associated with an increased OS in the first 2 years following diagnosis. Patients with FOLR1-negative, poor prognosis HGSC would be unlikely to benefit from anti-FOLR1 therapies. In contrast, a decreased PFS interval was observed for FOLR1-positive CCC. The clinical efficacy of FOLR1-targeted interventions should therefore be evaluated according to histology, stage and time following diagnosis.
- Published
- 2014
- Full Text
- View/download PDF
47. SMARCB1(INI1)-deficient sinonasal basaloid carcinoma: a novel member of the expanding family of SMARCB1-deficient neoplasms.
- Author
-
Agaimy A, Koch M, Lell M, Semrau S, Dudek W, Wachter DL, Knöll A, Iro H, Haller F, and Hartmann A
- Subjects
- Adult, Biopsy, Carcinoma secondary, Carcinoma therapy, Cell Nucleus chemistry, Fatal Outcome, Female, Humans, Immunohistochemistry, Magnetic Resonance Imaging, Male, Middle Aged, Paranasal Sinus Neoplasms pathology, Paranasal Sinus Neoplasms therapy, Paranasal Sinuses pathology, Predictive Value of Tests, SMARCB1 Protein, Time Factors, Treatment Outcome, Biomarkers, Tumor deficiency, Carcinoma chemistry, Chromosomal Proteins, Non-Histone deficiency, DNA-Binding Proteins deficiency, Paranasal Sinus Neoplasms chemistry, Paranasal Sinuses chemistry, Transcription Factors deficiency
- Abstract
Poorly differentiated sinonasal carcinomas are a heterogenous group of aggressive neoplasms that encompasses squamous cell carcinoma including basaloid variant, lymphoepithelial carcinoma, sinonasal undifferentiated carcinoma, and neuroendocrine-type small cell carcinoma. We herein describe 3 cases of a hitherto unreported variant combining features of basaloid carcinoma with variable intermingled rhabdoid cells. Patients were 2 women (aged 28 and 35) and a man (52 y) who presented with sinonasal masses. All had advanced local disease with bone involvement (pT4). None had a history of irradiation or a family history of rhabdoid tumors. Treatment was surgery and adjuvant chemoradiation. One patient developed liver, lung, pleural, and pericardial metastases (63 mo) and is currently (70 mo) alive under palliative treatment. Another developed recurrent cervical lymph node metastases and died of disease 8.5 years later. The youngest patient was disease-free at last follow-up 7 years later. Histologic features were very similar in all 3 cases and showed intimate admixture of compact basaloid cell nests with peripheral palisading, perivascular pseudorosettes, and a few scattered rhabdoid cells. Rhabdoid cells were more extensive in the metastasis in 1 case but formed a minor inconspicuous component in the primary tumors in all cases. Striking features common to all cases were (1) basaloid "blue" appearance at low power, (2) papilloma-like exophytic component, (3) extensive pagetoid surface growth with prominent denuding features, and (4) replacement of underlying mucous glands mimicking an inverted papilloma. Clear-cut origin from benign papilloma and overt squamous differentiation were lacking. Diffuse (2) or partial (1) p16 expression was noted, but all cases lacked human papillomavirus DNA by molecular tests. In situ hybridization was negative for Epstein-Barr virus. Immunohistochemistry showed diffuse expression of pancytokeratin. CK5 and vimentin showed intermingling of CK5/vimentin basaloid and CK5/vimentin rhabdoid cells. Complete loss of nuclear SMARCB1 expression was seen in all cases including also the denuding carcinoma in situ-like surface lesions. To our knowledge, this variant of sinonasal carcinoma has not been reported before. The identical features in all 3 cases suggest a specific disease rather than a nonspecific dedifferentiated phenotype. Awareness of this rare variant and thus reporting of additional cases is necessary for defining its full morphologic and biological spectrum.
- Published
- 2014
- Full Text
- View/download PDF
48. Incidental finding of a giant asymptomatic right atrial tumor.
- Author
-
Strecker T, Agaimy A, Zelzer P, Weyand M, and Wachter DL
- Subjects
- Echocardiography, Female, Heart Atria surgery, Heart Neoplasms surgery, Humans, Incidental Findings, Middle Aged, Myxoma surgery, Heart Atria pathology, Heart Neoplasms pathology, Myxoma pathology
- Abstract
Primary cardiac tumors are very rare, atrial myxoma being the most common benign tumor of the heart. They may present with a great variety of incidental asymptomatic masses to severe life-threatening cardiovascular complications necessitating emergency surgery. Here we report the diagnostic evaluation and successful surgical resection of such a giant cardiac tumor which was found on a routine medical check-up in a 62-year-old patient. Histology confirmed diagnosis of unusually huge myxoma. This article demonstrates it's necessary to include cardiac tumors in the differential diagnosis of subtle and non-specific cardiothoracic symptoms.
- Published
- 2014
49. HER2 and TOP2A amplification in a hospital-based cohort of breast cancer patients: associations with patient and tumor characteristics.
- Author
-
Fasching PA, Weihbrecht S, Haeberle L, Gasparyan A, Villalobos IE, Ma Y, Ekici AB, Wachter DL, Hartmann A, Beckmann MW, Slamon DJ, and Press MF
- Subjects
- Breast Neoplasms mortality, Breast Neoplasms pathology, Cohort Studies, Disease-Free Survival, Female, Genotype, Humans, In Situ Hybridization, Fluorescence, Kaplan-Meier Estimate, Poly-ADP-Ribose Binding Proteins, Polymorphism, Single Nucleotide, Real-Time Polymerase Chain Reaction, Tissue Array Analysis, Antigens, Neoplasm genetics, Breast Neoplasms genetics, DNA Topoisomerases, Type II genetics, DNA-Binding Proteins genetics, Gene Amplification, Receptor, ErbB-2 genetics
- Abstract
Gene amplification is an important factor for altered gene expression in breast cancers. TOP2A-amplification often occurs concomitantly with HER2 amplification, and it has been suggested to be predictive for the response to anthracycline chemotherapy. This study assessed the correlation between HER2 status and TOP2A co-amplification, the possible association of TOP2A single-nucleotide polymorphisms with the frequency of this co-amplification as well as confirmation of association with outcome. HER2 and TOP2A amplification were analyzed in a tissue microarray from a clinical cohort study. Additionally, a common genetic variant (rs13695) in the TOP2A gene was genotyped in germline DNA. HER2 gene amplification was compared with HER2-IHC findings assessed during clinical routine work, and the association between all the biomarkers analyzed and the clinical outcome was determined. As an exploratory aim, rs13695 genotypes were compared with TOP2A amplification status. HER2 amplification was seen in 101 of 628 (16.1 %) and TOP2A amplification in 32 (5.1 %) cancers. No TOP2A amplification occurred without HER2 co-amplification. HER2 amplification was found in 8, 13.6, and 55.1 % of patients with HER2-IHC 0/1+, 2+, and 3+ tumors, respectively. HER2-IHC was not associated with an effect on the prognosis, but HER2-FISH was. There was an association between the rs13695 genotype and TOP2A amplification status (P = 0.03). Although there was a significant correlation between HER2 status determined by IHC and HER2 by FISH, only HER2 gene amplification status by FISH was correlated with outcome indicating greater utility for FISH in routine clinical settings.
- Published
- 2014
- Full Text
- View/download PDF
50. [Sebaceous breast carcinoma: report of a rare histological special subtype].
- Author
-
Wachter DL, Rauh C, Wenkel E, Fasching PA, Beckmann MW, and Hartmann A
- Subjects
- Adenocarcinoma, Sebaceous diagnosis, Biomarkers, Tumor analysis, Biopsy, Needle, Breast pathology, Breast Neoplasms diagnosis, Carcinoma, Intraductal, Noninfiltrating diagnosis, Diagnosis, Differential, Female, Humans, Mammography, Middle Aged, Muir-Torre Syndrome diagnosis, Neoplasms, Hormone-Dependent diagnosis, Neoplasms, Hormone-Dependent pathology, Neoplasms, Multiple Primary diagnosis, Prognosis, Receptor, ErbB-2 analysis, Receptors, Estrogen analysis, Receptors, Progesterone analysis, Ultrasonography, Mammary, Adenocarcinoma, Sebaceous pathology, Breast Neoplasms pathology, Carcinoma, Intraductal, Noninfiltrating pathology, Muir-Torre Syndrome pathology, Neoplasms, Multiple Primary pathology
- Abstract
We report on a case of sebaceous carcinoma of the breast as a rare histological special subtype of breast cancer. Because these tumors are uncommon, differential diagnostic considerations and the exclusion of Muir-Torre syndrome are emphasized. Finally possible mechanisms of development and therapeutic strategies for this carcinoma are discussed.
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.